Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGSC 20% in primary immunodeficiency
2015-003290-15Phase 3Completed
- Sponsor
- Grifols
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of IgPro20 in Immunogenetic disorder, sponsored by Grifols. Primary endpoints: Number of serious bacterial infections and Percentage of subjects with serious bacterial infections. Started Jan 2016; status: completed.
02
Drugs
IgPro20
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2015-003290-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003290-15.